Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 2
2010 3
2011 7
2012 4
2013 5
2014 1
2015 2
2016 2
2017 9
2018 6
2019 2
2020 8
2021 14
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Neal B, et al. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605608 Free article. Clinical Trial.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Hernandez AF, et al. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. Lancet. 2018. PMID: 30291013 Clinical Trial.
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frigé C, De Cosmo S, Di Bartolo P, Di Cianni G, Fioretto P, Giorda CB, Pontremoli R, Russo G, Viazzi F, Nicolucci A; AMD Annals study group. Ceriello A, et al. Among authors: di bartolo p. Lancet Reg Health Eur. 2023 Jun 12;31:100666. doi: 10.1016/j.lanepe.2023.100666. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37547276 Free PMC article.
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Natalicchio A, et al. Among authors: di bartolo p. Crit Rev Oncol Hematol. 2022 Jan;169:103572. doi: 10.1016/j.critrevonc.2021.103572. Epub 2021 Dec 22. Crit Rev Oncol Hematol. 2022. PMID: 34954047 Review.
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, Ferrari P, D'Oronzo S, Gori S, Russo A, Acquati S, Gallo M. Silvestris N, et al. Among authors: di bartolo p. Crit Rev Oncol Hematol. 2020 Oct;154:103066. doi: 10.1016/j.critrevonc.2020.103066. Epub 2020 Aug 15. Crit Rev Oncol Hematol. 2020. PMID: 32853883 Free article. Review.
Diabetic ketoacidosis: A consensus statement of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology and Pediatric Diabetoloy (SIEDP).
Lapolla A, Amaro F, Bruttomesso D, Di Bartolo P, Grassi G, Maffeis C, Purrello F, Tumini S. Lapolla A, et al. Among authors: di bartolo p. Nutr Metab Cardiovasc Dis. 2020 Sep 24;30(10):1633-1644. doi: 10.1016/j.numecd.2020.06.006. Epub 2020 Jun 18. Nutr Metab Cardiovasc Dis. 2020. PMID: 32771260 Review.
Consensus report of the joint workshop of the Italian Society of Diabetology, Italian Society of Periodontology and Implantology, Italian Association of Clinical Diabetologists (SID-SIdP-AMD).
Adda G, Aimetti M, Citterio F, Consoli A, Di Bartolo P, Landi L, Lione L, Luzi L. Adda G, et al. Among authors: di bartolo p. Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2515-2525. doi: 10.1016/j.numecd.2021.03.015. Epub 2021 Mar 27. Nutr Metab Cardiovasc Dis. 2021. PMID: 34238654 Review.
65 results